SCHEDULE: CEO Blair Jordan's Stake in 180 Life Sciences Corp. Updated Following Share Adjustments and New Option Grants

Blair Jordan, CEO of 180 Life Sciences Corp., has updated his beneficial ownership to 31.3% of common stock, reflecting adjustments to restricted stock grants and new option awards, as detailed in an amended Schedule 13D filing.

Summary

• Amendment No. 3 to Schedule 13D was filed by Blair Jordan to update and correct the number of restricted stock shares issued to him on June 17, 2025, which the Board of Directors retroactively adjusted to comply with the total number of shares available under the Third Amended and Restated 2022 Omnibus Incentive Plan.
• Blair Jordan's aggregate beneficial ownership is 1,888,742 shares, representing 31.3% of the Issuer's common stock outstanding as of July 1, 2025 (6,039,209 shares).
• Beneficial ownership includes 160,000 shares with sole voting and dispositive power, and 1,721,166 shares with shared voting power.
• Shared voting power stems from irrevocable voting proxies for 43,166 shares from Dr. James Woody, 200,000 shares from Dr. Marlene Krauss, and 1,318,000 shares from Elray Resources, Inc.
• On June 17, 2025, 160,000 shares of restricted common stock originally issued to Mr. Jordan in February 2025 had their vesting accelerated to full vesting.
• On June 17, 2025, Blair Jordan Strategy and Finance Consulting Inc. (owned by Mr. Jordan) was granted 167,576 shares of restricted common stock, vesting 50% on the six-month and 50% on the twelve-month anniversaries of the grant date.
• On June 17, 2025, Blair Jordan Strategy and Finance Consulting Inc. was also granted options to purchase 410,000 shares of common stock under the 2025 Option Incentive Plan, with an exercise price of $0.9290 per share, vesting 50% on the six-month and 50% on the twelve-month anniversaries of the grant date.
• The 2025 Option Incentive Plan requires stockholder approval; options cannot be exercised prior to approval, and the plan can be unwound and options cancelled if approval is not obtained.

Sentiment

Score: 7

Explanation: The document indicates strong alignment between the CEO and the company's interests through significant beneficial ownership and ongoing compensation, reflecting stability in leadership. The proactive adjustment of share grants for compliance is a positive sign of good governance. However, the need for stockholder approval for the 2025 Option Incentive Plan introduces a minor contingency.

Positives

• Increased alignment between CEO Blair Jordan and shareholder interests through significant beneficial ownership (31.3%).
• The Board of Directors and Compensation Committee proactively managed share grants to ensure compliance with the existing incentive plan limits, demonstrating good corporate governance.
• The grant of new options and restricted stock incentivizes the CEO's continued service and performance, aligning executive compensation with long-term company goals.

Risks

• The 2025 Option Incentive Plan, under which 410,000 options were granted, has not yet been approved by the Company's stockholders. If stockholder approval is not obtained, the plan can be unwound, and the outstanding options cancelled, potentially impacting executive incentives.

Future Outlook

Blair Jordan may purchase additional securities of the Issuer or dispose of some or all of his currently owned securities in the future, depending on general market and economic conditions. He may also acquire additional shares of common stock under various employee benefit and compensation arrangements with the Company. He retains the right to change his investment intent and modify his plans regarding securities transactions.

Industry Context

This filing reflects standard corporate governance practices regarding executive compensation and beneficial ownership disclosures for publicly traded companies. The use of voting agreements is a mechanism to consolidate voting power, often seen in situations where management seeks to ensure stability or support for board recommendations.

Corporate Governance

Related Party Transactions

• Executive Consulting Agreement between the Issuer, Blair Jordan, and Blair Jordan Strategy and Finance Consulting Inc. (an entity owned by Mr. Jordan).
• Grant of restricted common stock and stock options to Blair Jordan Strategy and Finance Consulting Inc., an entity owned and controlled by Mr. Jordan.
• Voting Agreements with Dr. James Woody, Dr. Marlene Krauss, and Elray Resources, Inc., granting irrevocable voting proxies to Blair Jordan, which consolidate voting power for the benefit of the Issuer.

Stakeholder Impact

• Shareholders: Increased transparency regarding the CEO's beneficial ownership and compensation structure. Potential future dilution from option exercises if the 2025 Plan is approved. Enhanced alignment of the CEO's interests with long-term shareholder value.
• Management/Employees: The CEO's compensation structure is detailed, providing clarity on incentives and reflecting ongoing commitment to executive retention and performance.

Next Steps

• Stockholder approval for the 2025 Option Incentive Plan is required for the exercise of granted options.
• Future vesting of 167,576 restricted shares on the six and twelve-month anniversaries of June 17, 2025.
• Future vesting of 410,000 options on the six and twelve-month anniversaries of June 17, 2025.
• Potential future purchases or dispositions of securities by Blair Jordan.

Key Dates

Recommendation

Keywords

180 Life Sciences Corp., Blair Jordan, Schedule 13D, beneficial ownership, restricted stock, stock options, voting agreement, corporate governance, executive compensation, SEC filing, common stock, NASDAQ